GlassScriptPhysician profile
Christopher D Hayes
NPI 1770669863
$12,863.54
in general payments reported to CMS, 2019-2025
49 companies · $2,099 in 2025
The $2,099 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,013 · 2020: $817 · 2021: $1,508 · 2022: $1,922 · 2023: $1,865 · 2024: $1,638 · 2025: $2,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,602.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,789.38 | 2019-2025 | |
| Abbvie INC. | $1,389.69 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,337.74 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,197.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,150.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $892.12 | 2019-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $532.28 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $483.53 | 2019-2024 | Steglatro, Segluromet, Belsomra |
| Glaxosmithkline, LLC. | $366.86 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $320.81 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $313.91 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $309.67 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $280.58 | 2019-2022 | |
| Abbott Laboratories | $275.70 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $267.90 | 2022-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.